Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Bio-Techne’s (TECH) Protein Science Momentum Faces a Double Whammy—Are Tariffs and NIH Cuts Undermining the Recovery?
Bio-Techne delivered a resilient Q3 FY25 print, posting 6% organic growth and 190bps margin expansion to 34.9%, outperforming peers amid macro volatility and highlighting disciplined execution. Strength was anchored by Protein Sciences (+7% organic), with notable traction in GMP reagents (TTM +13%) and Maurice instruments, alongside accelerating demand for organoid-related reagents (+20%), a secular vector supported by recent FDA shifts away from animal testing. Spatial biology and diagnostics posted 2% organic growth, with ExoDx prostate test volume up 30% YTD and COMET spatial placements growing double digits, despite NIH budget uncertainty and order timing noise. Management's confidence in neutralizing a ~$20M EBIT tariff drag by FQ1 FY26 via regionalized manufacturing, pricing, and logistics realignment demonstrates strong cross-functional agility. While exposure to NIH (~6% revenue) and escalating policy risk adds overhang—especially with proposed funding caps—Bio-Techne appears well-positioned, given its overindexation to chronic disease research and the NIH’s historical bipartisan funding support. New platform innovations and a refreshed $500M buyback authorization further signal capital strength and long-term optionality. With shares materially undervalued and structural growth intact, the near-term risks appear more sentiment-driven than fundamental. Can Bio-Techne sustain its margin and innovation trajectory as policy and geopolitical risks threaten to cloud the broader life sciences demand picture?
